CALCIPHYLAXIS AFTER KIDNEY TRANSPLANTATION: 
A RARE BUT LIFE-THREATENING DISORDER

Manuel Alfredo Podestà¹, Paola Ciceri², Andrea Galassi¹ and Mario Cozzolino¹

¹Renal Division, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Italy
²Department of Nephrology, Dialysis and Renal Transplant, Renal Research Laboratory, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy

Running head: Calciphylaxis in Renal Transplantation

Correspondence to: Mario Cozzolino; E-mail: mario.cozzolino@unimi.it

© Crown copyright 2021. This Open Access article contains public sector information licensed under the Open Government Licence v3.0 (https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/).
ABSTRACT
Calciphylaxis is a rare disorder characterized by vascular calcification and thrombosis of the subcutaneous microcirculation, leading to painful necrotic skin lesions and bearing a dreadfully high mortality rate. This syndrome is frequently also termed uremic calcific arteriolopathy, since most cases are observed in patients with kidney failure. However, it is increasingly clear that calciphylaxis may also affect patients with normal or only slightly impaired renal function, including kidney transplant recipients. A precise definition of the characteristics and risk factors of calciphylaxis developing after kidney transplantation has been hindered by the extreme rarity of this condition, which also hampered the development of effective therapeutic strategies.

In the present issue of CKJ, Guillén and colleagues report the largest case series of calciphylaxis in kidney transplant recipients to date, outlining several features that are apparently specific of this population. In this editorial, we briefly present the epidemiology and pathogenesis of calciphylaxis in different patient populations and discuss recent findings for its therapeutic management.

Keywords: calcific uremic arteriolopathy, chronic kidney disease, renal transplantation, vascular calcification
**SCOPE OF THE PROBLEM**

Calciphylaxis is an extremely rare syndrome characterized by vascular calcification and thrombosis of the subcutaneous microcirculation. Ensuing ischemia results in multiple painful skin lesions, which rapidly progress to ulceration with black eschars once necrosis of epidermal and adipose tissue has developed (1). Short-term prognosis is poor, usually due to superimposed infections resulting in sepsis (2–4).

Since calciphylaxis is typically observed in patients with kidney failure, this syndrome is frequently also termed uremic calcific arteriolopathy (2,3,5). Chronic kidney disease is associated with progressive vascular calcification, and uremia leads to extensive alterations in bone mineral handling that may predispose to calciphylaxis. However, several case series have clarified that calciphylaxis may also seldom affect patients with normal or only slightly impaired renal function, including kidney transplant recipients (3,6).

Large national databases have allowed a systematic assessment of calciphylaxis features in patients with kidney failure on renal replacement therapy. The incidence rate of calciphylaxis has been estimated at 0.4-3.5 per 1000 patients/year in US and European hemodialysis units (2,3,7), whereas the incidence may be higher for patients on peritoneal dialysis (Table 1) (8).

These studies identified relevant risk factors in this population, which comprise female sex, obesity, diabetes mellitus, hyperparathyroidism and length of dialysis vintage. In addition, several medications have been identified as possible facilitators of calciphylaxis development, including oral anticoagulants based on vitamin K antagonism (2,8,9). However, due to the extreme rarity of this disease in non-uremic patients, comparatively large case series of kidney transplant recipients are not available.

**MULTIFACTORIAL PATHOGENESIS**

Vascular calcification in chronic kidney disease does not entail a merely passive deposition of hydroxyapatite crystals in arterial walls, but is rather an actively regulated process in which pro-calcifying stimuli outbalance the protective effect of calcification inhibitors (10). These alterations induce transdifferentiation of vascular smooth muscle cells (VSMC) towards an osteochondrogenic phenotype, which results in arterial remodeling and mineralization. In uremic patients, calcium-phosphate imbalances, oxidative stress and comorbidities (e.g. diabetes mellitus and hypertension) concur in causing vascular calcification (11).
Despite the resolution of uremia after kidney transplantation, vascular calcification may still develop and progress in these patients due to the effect of other risk factors, such as inflammation, immunosuppression and calcification inhibitor deficit (12). The latter seem to be pivotal in the pathogenesis of calciphylaxis, with several studies suggesting a role for reduced matrix-Gla protein (MGP) and fetuin-A levels. MGP is a calcium-chelating protein and a potent inhibitor of VSMC trans-differentiation, whose activation relies on vitamin K-dependent carboxylation (13). Vitamin K deficit, a common occurrence in both uremic patients and kidney transplant recipients, is associated with high levels of uncarboxylated – i.e. inactivated – MGP, which represent an independent predictor of vascular calcification (14). High levels of uncarboxylated MGP have been reported in skin biopsies and in the serum of patients with calciphylaxis, and have been associated with vitamin K deficiency (15,16). This may in part explain the association of vitamin K antagonist use and the development of calciphylaxis in uremic patients. Similarly, low levels of fetuin-A, a circulating glycoprotein that complexes amorphous phosphate, have been reported in patients with calciphylaxis (17). Thrombosis of the microcirculation has been increasingly recognized as a crucial precipitative factor in the development of calciphylaxis, which frequently ensues as a consequence of traumatic events. Interestingly, a hypercoagulable state seems to be highly prevalent in these patients (18), providing a possible explanation for the rarity of this condition.

Calciphylaxis in Kidney Transplant Recipients

In the present issue of CKJ, Guíllén and colleagues report the largest case series of calciphylaxis in kidney transplant recipients to date, obtained from a monocentric retrospective data search spanning over 30 years (19). The authors also conducted a systematic review of cases published in international literature during the last 50 years, adding up to a total of 45 patients, to provide a meaningful description of disease features in this population.

A significant proportion of kidney transplant recipients who developed calciphylaxis had moderate graft dysfunction and a relatively long dialysis vintage (median 24 months), along with a past history of graft failure that led to re-transplantation. In addition, calciphylaxis developed during the first year of transplantation in almost half of these patients, suggesting a likely carry-over effect of uremia-related risk factors.
Calciphylaxis in this cohort had some key differences when compared to features typically observed in patients with kidney failure (Table 1). There was no female predominance, with a roughly even frequency of males and females, and only one quarter of patients had diabetes. In addition, lesions distribution was mostly peripheral, contrasting with the distinct preponderance of central lesions (i.e. involving areas with abundance of adipose tissue such as abdomen and thighs) observed in hemodialysis patients (2,3).

Altered parathormone levels were observed in most patients, and the study confirmed a high frequency of use of vitamin K antagonists in kidney transplant recipients with calciphylaxis, suggesting that vitamin K deficiency may indeed play a significant role also in these patients. Mortality was unfortunately high also in this cohort, with an overall short-term survival of 44%.

To account for changes in the standard of care of kidney transplant recipients over the last three decades, the authors also compared the characteristics of cases diagnosed before and after 2000. Despite differences in immunosuppressive regimens and demographic features (patients diagnosed after the year 2000 were older and with longer dialysis vintage), most of the other characteristics were comparable between groups.

**TREATMENT OPTIONS**

Calciphylaxis is a complex syndrome that requires a multidisciplinary approach, including wound care, analgesia and removal of known risk factors. Despite advances in the understanding of calciphylaxis pathogenesis, therapeutic management is still based on expert consensus and there are no currently approved treatment for this condition (20). Due to the extreme rarity of calciphylaxis in kidney transplant recipients, virtually all available data on treatment derives from patients on hemodialysis.

Normalization of calcium-phosphate metabolism is a reasonable first step, along with removal of possible iatrogenic factors, including calcium supplements, vitamin D analogs and vitamin K antagonists (1,21). In dialysis patients, longer or more frequent dialysis sessions with low-calcium dialysate may improve metabolic control and enhance wound healing (1,22). In patients with severe hyperparathyroidism, the use of calcimimetics or parathyroidectomy could be beneficial (23,24). Bisphosphonates have been also successfully used to inhibit the progression of lesions in some patient series (25), but no prospective trials have been conducted to date.
Sodium thiosulfate, an inorganic sodium salt with antioxidant and vasodilator properties, is among the most used agent for calciphylaxis treatment. Retrospective data suggested a good efficacy-safety profile, with most patients improving after administration (26). Three randomized controlled trials had been planned to prospectively assess the efficacy of sodium thiosulfate (NCT03150420, NCT02527213 and ISRCTN73380053), but they were all terminated early due to insufficient patient enrolment.

Other promising therapeutic alternatives include hyperbaric oxygen therapy to improve transcutaneous oxygen tension, rheopheresis and bosentan to reduce blood viscosity and promote arteriolar vasodilation, as well as non–vitamin K antagonist anticoagulants to salvage thrombosis of the microcirculation (1,27).

A recent meta-analysis of case series and cohort studies failed to show any clear benefit on mortality from all the therapies explored, including thiosulphate, parathriroidectomy, cinacalcet, hyperbaric oxygen therapy, and bisphosphonates (28). However, quality of evidence was low and results were inconclusive, reflecting the lack of randomized controlled trials that explored the effect of these treatments.

Increasing MGP carboxylation through vitamin K supplementation has been proposed as a possible additional therapeutic strategy for calciphylaxis. Preliminary results from a phase II trial (NCT02278692) comparing vitamin K1 with placebo in hemodialysis patients suggested a relevant clinical efficacy, with a benefit on both lesion size and mortality at 12 weeks (29).

Finally, the use of SNF472, a polyphosphate compound that inhibits hydroxyapatite crystal formation, has been recently explored in a phase 2 single-arm open label study on 14 hemodialysis patients with calciphylaxis. Treatment was well-tolerated, and led to improvements in wound size, pain, and quality of life at 12 weeks (30). A phase 3 randomized clinical trial has been planned to evaluate the efficacy of SNF472 with placebo (31).

CONFLICT OF INTEREST STATEMENT
Nothing to declare.
REFERENCES

1. Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. The New England Journal of Medicine 2018; 379: 399–400.

2. Nigwekar SU, Zhao S, Wenger J et al. A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors. Journal of the American Society of Nephrology: JASN 2016; 27: 3421–3429.

3. Brandenburg VM, Kramann R, Rothe H et al. Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 2017; 32: 126–132.

4. Weenig RH, Sewell LD, Davis MDP, McCarthy JT, Pittelkow MR. Calciphylaxis: natural history, risk factor analysis, and outcome. Journal of the American Academy of Dermatology 2007; 56: 569–579.

5. Musso CG, Enz PA, Kowalczuk A, Cozzolino M, Brandenburg V, Nigwekar S. Differential diagnosis of calciphylaxis in chronic dialysis patients. International Urology and Nephrology 2020; 52: 595–597.

6. Bajaj R, Courbebaisse M, Kroshinsky D, Thadhani RI, Nigwekar SU. Calciphylaxis in Patients With Normal Renal Function: A Case Series and Systematic Review. Mayo Clinic Proceedings 2018; 93: 1202–1212.

7. Brandenburg V, Adragao T, van Dam B et al. Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet). Clinical Kidney Journal 2015; 8: 567–571.

8. Zhang Y, Corapi KM, Luongo M, Thadhani R, Nigwekar SU. Calciphylaxis in peritoneal dialysis patients: a single center cohort study. International Journal of Nephrology and Renovascular Disease 2016; 9: 235–241.

9. Hayashi M, Takamatsu I, Kanno Y et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 2012; 27: 1580–1584.

10. Covic A, Vervloet M, Massy ZA et al. Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. The Lancet. Diabetes & Endocrinology 2018; 6: 319–331.
11. Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A. Cardiovascular disease in dialysis patients. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 2018; 33: iii28–iii34.

12. Podestà MA, Cucchiari D, Ciceri P, Messa P, Torregrosa J-V, Cozzolino M. Cardiovascular calcifications in kidney transplant recipients. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 2021; : gfab053.

13. Cozzolino M, Cianciolo G, Podestà MA et al. Current Therapy in CKD Patients Can Affect Vitamin K Status. Nutrients 2020; 12.

14. Jaminon AMG, Dai L, Qureshi AR et al. Matrix Gla protein is an independent predictor of both intimal and medial vascular calcification in chronic kidney disease. Scientific Reports 2020; 10: 6586.

15. Kramann R, Brandenburg VM, Schurgers LJ et al. Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 2013; 28: 856–868.

16. Nigwekar SU, Bloch DB, Nazarian RM et al. Vitamin K–Dependent Carboxylation of Matrix Gla Protein Influences the Risk of Calciphylaxis. Journal of the American Society of Nephrology : JASN 2017; 28: 1717–1722.

17. Schafer C, Heiss A, Schwarz A et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. The Journal of Clinical Investigation 2003; 112: 357–366.

18. Dobry AS, Ko LN, St John J, Sloan JM, Nigwekar S, Kroshinsky D. Association Between Hypercoagulable Conditions and Calciphylaxis in Patients With Renal Disease. JAMA Dermatology 2018; 154: 182–187.

19. Guillén E, Torregrosa JV, Garcia-Herrera A, Ganau S, Diekmann F, Cucchiari D. Development of calciphylaxis in kidney transplant recipients with a functioning graft. Clinical Kidney Journal [Internet] 2021; [cited 2021 Nov 14] Available from: https://doi.org/10.1093/ckj/sfab205

20. Brandenburg VM, Evenepoel P, Floege J et al. Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis? Nephrology, Dialysis, Transplantation: Official
Publication of the European Dialysis and Transplant Association - European Renal Association 2016; 31: 1211–1219.

21. Portales-Castillo I, Kroshinsky D, Malhotra CK et al. Calciphylaxis-as a drug induced adverse event. Expert Opinion on Drug Safety 2019; 18: 29–35.

22. Lipsker D, Chosidow O, Martinez F, Challier E, Francès C. Low-Calcium Dialysis in Calciphylaxis. Archives of Dermatology 1997; 133: 798–799.

23. Velasco N, MacGregor MS, Innes A, MacKay IG. Successful treatment of calciphylaxis with cinacalcet—an alternative to parathyroidectomy? Nephrology Dialysis Transplantation 2006; 21: 1999–2004.

24. Arch-Ferrer JE, Beenken SW, Rue LW, Bland KI, Diethelm AG. Therapy for calciphylaxis: an outcome analysis. Surgery 2003; 134: 941–944; discussion 944-945.

25. Torregrosa J-V, Sánchez-Escuredo A, Barros X, Blasco M, Campistol JM. Clinical management of calcific uremic arteriolopathy before and after therapeutic inclusion of bisphosphonates. Clinical Nephrology 2015; 83: 231–234.

26. Peng T, Zhuo L, Wang Y et al. Systematic review of sodium thiosulfate in treating calciphylaxis in chronic kidney disease patients. Nephrology (Carlton, Vic.) 2018; 23: 669–675.

27. An J, Devaney B, Ooi KY, Ford S, Frawley G, Menahem S. Hyperbaric oxygen in the treatment of calciphylaxis: A case series and literature review. Nephrology (Carlton, Vic.) 2015; 20: 444–450.

28. Udomkarnjananun S, Kongnatthasate K, Pradipornsilpa K, Eiam-Ong S, Jaber BL, Susantitaphong P. Treatment of Calciphylaxis in CKD: A Systematic Review and Meta-analysis. Kidney International Reports 2019; 4: 231–244.

29. Nigwekar S. Phase 2 Trial of Phytonadione in Calciphylaxis [Internet]. 2019; [cited 2021 Nov 21] Available from: https://www.asn-online.org/education/kidneyweek/2019/program-abstract.aspx?controlId=3272026

30. Brandenburg VM, Sinha S, Torregrosa J-V et al. Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis. Journal of Nephrology 2019; 32: 811–821.
31. Sinha S, Gould LJ, Nigwekar SU et al. The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis. Clinical Kidney Journal [Internet] 2021; [cited 2021 Nov 21] Available from: https://doi.org/10.1093/ckj/sfab117
Table 1. Clinical features of calciphylaxis in hemodialysis patients, peritoneal dialysis patients and kidney transplant recipients. VKA: vitamin K antagonists; PTH: parathormone.

|                         | Hemodialysis (2,3) | Peritoneal Dialysis (8) | Kidney Transplant (19) | Non-uremic (6) |
|-------------------------|--------------------|-------------------------|------------------------|----------------|
| **Incidence (per 1000 patient/years)** | 0.4-3.5            | 9.0                     | -                      | -              |
| **Median Age (years)**  | 54-70              | 50                      | 44                     | 60             |
| **Females (%)**         | 63-67              | 71                      | 48                     | 77             |
| **Central Lesions (%)** | 82                 | -                       | 36                     | 61             |
| **VKA Use (%)**         | 14-51              | 71                      | 39                     | 47             |
| **Diabetes mellitus (%)** | 55-61             | 43                      | 23                     | 32             |
| **Altered PTH levels (%)** | -                 | 57                      | 75                     | 25             |
| **Mortality**            | 45-80% at 1 year | 71% at 1 year           | 56% overall           | Median survival: 4.2 months. |